When reviewing the literature for patients on JAK1 and JAK2 inhibitors that developed coccidioidomycosis, a case series by Kusne et al. documents eight cases of coccidioidomycosis in patients receiving ruxolitinib in endemic regions of the San Joaquin Valley of California and Arizona. This evidence concerns the gene JAK2 and coccidioidomycosis.